Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study

Syed M. Mohiuddin, Carl J. Pepine, Maureen T. Kelly, Susan M. Buttler, Carolyn M. Setze, Darryl J. Sleep, James C. Stolzenbach

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

Background: Patients with mixed dyslipidemia often require combination therapy to effectively control lipid abnormalities. This study compared the effects of combination therapy with ABT-335 (a new formulation of fenofibric acid) and simvastatin to ABT-335 and simvastatin monotherapies on lipid and nonlipid parameters in patients with mixed dyslipidemia. Methods: This was a phase 3, multicenter, randomized, double-blind, active-controlled study. A total of 657 patients with mixed dyslipidemia (low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL, triglycerides [TGs] ≥150 mg/dL, and high-density lipoprotein cholesterol [HDL-C]

Original languageEnglish (US)
Pages (from-to)195-203
Number of pages9
JournalAmerican Heart Journal
Volume157
Issue number1
DOIs
StatePublished - Jan 1 2009

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study'. Together they form a unique fingerprint.

  • Cite this